UBS AM
VRDN icon

UBS AM’s Viridian Therapeutics VRDN Stock Holding History

UBS AM’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
999,915
+111,617
+13% +$1.8M ﹤0.01% 975
2026
Q1 		$17.4M Buy
888,298
+748,938
+537% +$22.2M ﹤0.01% 939
2025
Q4 		$4.34M Buy
139,360
+380
+0.3% +$10.4K ﹤0.01% 1530
2025
Q3 		$3M Sell
138,980
-51,124
-27% -$922K ﹤0.01% 1591
2025
Q2 		$2.66M Buy
190,104
+59,534
+46% +$808K ﹤0.01% 2020
2025
Q1 		$1.76M Buy
130,570
+14,788
+13% +$252K ﹤0.01% 2050
2024
Q4 		$2.22M Buy
115,782
+26,286
+29% +$572K ﹤0.01% 1984
2024
Q3 		$2.04M Buy
89,496
+20,166
+29% +$330K ﹤0.01% 2024
2024
Q2 		$902K Buy
69,330
+41,021
+145% +$568K ﹤0.01% 2430
2024
Q1 		$496K Buy
28,309
+13,148
+87% +$255K ﹤0.01% 2286
2023
Q4 		$330K Hold
15,161
– – ﹤0.01% 2407
2023
Q3 		$233K Sell
15,161
-8,460
-36% -$161K ﹤0.01% 2485
2023
Q2 		$601K Hold
23,621
– – ﹤0.01% 2246
2023
Q1 		$601K Buy
23,621
+4,151
+21% +$133K ﹤0.01% 2246
2022
Q4 		$569K Buy
+19,470
New +$449K ﹤0.01% 2130

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS AM's VRDN Position: Q2 2026 in Review

UBS AM increased its Viridian Therapeutics (VRDN) stake by 13% in Q2 2026, buying an estimated $1.8M and bringing the position to 999,915 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #975.

UBS AM first reported a position in VRDN in Q4 2022 and has held it in 15 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • UBS AM held 999,915 shares of Viridian Therapeutics worth $18.4M as of Q2 2026.
  • UBS AM bought 111,617 Viridian Therapeutics shares in Q2 2026, an estimated $1.8M.
  • Viridian Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #975 holding.
  • UBS AM first reported a position in Viridian Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.